WO 2005/075440 PCT/GB2005/000341

Claims

## 1. A compound of formula (I);

5

10

15

20

25

30

wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;  $R^1$  is selected from hydrogen,  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, or halosubstituted $C_{1-6}$  alkyl;  $R^2$  is  $(CH_2)_m R^3$  where m is 0 or 1;

or R<sup>1</sup> and R<sup>2</sup> together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

 $R^3$  is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted  $C_{3-8}$  cycloalkyl group, an unsubstituted or substituted straight or branched  $C_{1-10}$  alkyl, an unsubstituted or substituted  $C_{5-7}$  cycloalkenyl or  $R^5$ ;

 $R^4$  is selected from hydrogen,  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, or halosubstituted $C_{1-6}$  alkyl, COCH<sub>3</sub>, or SO<sub>2</sub>Me;

R<sup>5</sup> is



wherein p is 0, 1 or 2, and X is CH<sub>2</sub>, O, S, SO or SO<sub>2</sub>;

 $R^6$  is  $(C_{3-6})$  cycloalkyl, 4- to 7- membered non aromatic heterocyclic group or unsubstituted  $C_{2-6}$  alkyl or substituted  $(C_{1-6})$  alkyl;

R<sup>7</sup> is OH, C<sub>1-6</sub>alkoxy, NR<sup>8a</sup>R<sup>8b</sup>, NHCOR<sup>9</sup>, NHSO<sub>2</sub>R<sup>9</sup>, SOqR<sup>9</sup>;

R<sup>8a</sup> is H or C<sub>1-6</sub>alkyl;

R<sup>8b</sup> is H or C<sub>1-6</sub>alkyl;

R<sup>9</sup> is C<sub>1-6</sub>alkyl;

q is 0, 1 or 2;

and pharmaceutically acceptable derivatives thereof,

wherein R<sup>6</sup> is not CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3.

- 35 2. A compound as claimed in claim 1 wherein X is CH<sub>2</sub>, O or S.
  - 3. A compound as claimed in claim 1 or 2 wherein R<sup>6</sup> is (C<sub>3-6</sub>)cycloalkyl, 4- to 7- membered non aromatic heterocyclic group or unsubstituted C<sub>2-6</sub>alkyl.
- 40 4. A compound as claimed in claim 1 wherein compounds of formula (I) are compounds of formula (Ia):

WO 2005/075440 PCT/GB2005/000341

wherein:

5

30

R<sup>3</sup> is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group; R<sup>6</sup> is unsubstituted or substituted C<sub>2-6</sub>alkyl;

 $R^{11}$  is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy; d is 0, 1, 2 or 3;

and pharmaceutically acceptable derivatives thereof.

- A compound as claimed in any one of claims 1, 2 or 4 wherein R<sup>6</sup> is either ethyl,
  substituted ethyl, isopropyl or tert-butyl.
  - 6. A compound as claimed in any preceding claim selected from Example 1 to 5.
- 7. A pharmaceutical composition comprising a compound as claimed in claims 1 to 6 or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.
  - 8. A pharmaceutical composition as claimed in claim 7 further comprising a second theraputic agent.
- 9. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or (Ia) as claimed in claims 1 to 6 or a pharmaceutically acceptable derivative thereof.
- 25 10. A method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) or formula (Ia) as claimed in claims 1 to 6 or a pharmaceutically acceptable derivative thereof.